Oppenheimer Holdings, Inc. set a $18.00 price objective on Kura Oncology, Inc. (NASDAQ:KURA) in a research note issued to investors on Thursday. The firm currently has a buy rating on the stock.

KURA has been the subject of several other research reports. ValuEngine downgraded Kura Oncology from a hold rating to a sell rating in a research report on Friday, September 1st. Zacks Investment Research downgraded Kura Oncology from a buy rating to a hold rating in a research report on Wednesday, September 6th. Cann restated a buy rating on shares of Kura Oncology in a research report on Wednesday, November 8th. Leerink Swann restated an outperform rating and set a $18.00 target price (up previously from $16.00) on shares of Kura Oncology in a research report on Thursday, August 10th. Finally, Cowen and Company started coverage on Kura Oncology in a research report on Thursday, September 7th. They issued an outperform rating for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $17.60.

Kura Oncology (NASDAQ:KURA) traded up $0.20 during trading on Thursday, hitting $15.75. The company had a trading volume of 157,623 shares, compared to its average volume of 283,468. The company has a quick ratio of 13.48, a current ratio of 13.48 and a debt-to-equity ratio of 0.07. Kura Oncology has a 1-year low of $4.72 and a 1-year high of $16.75.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). equities research analysts forecast that Kura Oncology will post -1.45 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Oppenheimer Holdings, Inc. Analysts Give Kura Oncology, Inc. (KURA) a $18.00 Price Target” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/11/19/oppenheimer-holdings-inc-analysts-give-kura-oncology-inc-kura-a-18-00-price-target.html.

A number of institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System raised its position in Kura Oncology by 24.5% in the 3rd quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock valued at $471,000 after purchasing an additional 6,200 shares during the last quarter. Nationwide Fund Advisors raised its position in Kura Oncology by 66.2% in the 2nd quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock valued at $240,000 after purchasing an additional 10,258 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Kura Oncology in the 2nd quarter valued at $102,000. Rhumbline Advisers bought a new position in Kura Oncology in the 2nd quarter valued at $131,000. Finally, Schwab Charles Investment Management Inc. raised its position in Kura Oncology by 61.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 39,200 shares of the company’s stock valued at $587,000 after purchasing an additional 14,900 shares during the last quarter. Hedge funds and other institutional investors own 39.11% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.